Crystalline Polymorphs of DBD for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly those involving 1,6-dibromo-1,6-dideoxy-dulcitol (DBD), face challenges in safety during manufacturing and poor solubility, with existing methods being inefficient and often palliative, necessitating the development of new, safer, and more effective cancer therapies.
Innovation Solution
Development of crystalline polymorphic forms of DBD with specific x-ray powder diffraction patterns and differential scanning calorimetry profiles, which can be used in pharmaceutical compositions and administered alone or in combination with other therapies, including radiation therapy and DNA repair inhibitors, to treat various types of cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional methods are used to prepare DBD, then the compound can be synthesized, but the manufacturing process becomes unsafe and the solubility remains poor
Solution Approach 1:
The patent changes the physical state parameter of DBD by developing crystalline polymorphic forms with specific crystal structures. This transformation from amorphous or conventional crystalline forms to new polymorphic forms with defined unit cell dimensions and space groups improves both manufacturing safety through controlled crystallization processes and enhances solubility characteristics while maintaining compound identity and activity
Solution Approach 2:
The patent utilizes phase transition principles by inducing formation of specific crystalline polymorphic forms through controlled crystallization processes. By managing the phase transition from solution or melt to specific crystal structures with defined polymorphic forms, the invention achieves safer manufacturing conditions and improved solubility while preserving the pharmacological activity of DBD
2Stability of the object's composition
If new crystalline polymorphic forms are developed, then stability and solubility improve, but the complexity of characterization and manufacturing increases
Solution Approach 1:
The patent replaces complex manual characterization procedures with automated analytical techniques including X-ray diffraction for crystal structure determination, differential scanning calorimetry for thermal analysis, and mass spectrometry for molecular weight verification. This substitution of mechanical/manual methods with automated analytical systems reduces the operational complexity of characterizing new polymorphic forms while ensuring comprehensive validation of compound stability and identity
3Reliability
If DBD is used as cancer therapy, then antitumor effect is achieved, but current treatments are mostly palliative with limited long-term cure
Solution Approach 1:
The patent changes the physical and chemical parameters of DBD by developing new crystalline polymorphic forms with optimized crystal structures, unit cell dimensions, and packing arrangements. These parameter changes in the physical state and molecular arrangement enhance the pharmacological properties of DBD, improving antitumor efficacy and extending duration of action by enhancing cellular uptake, stability, and mechanism of action while reducing resistance development
Solution Approach 2:
The patent explores composite formulations combining DBD polymorphic forms with adjuvants, carriers, or combination therapies to enhance antitumor activity. By creating composite treatment systems that integrate DBD with other anticancer agents or delivery systems, the invention extends the duration of therapeutic action and improves long-term cure rates through synergistic effects while maintaining the core antitumor properties of DBD
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline polymorphic forms of DBD exhibit improved stability, safety, and efficacy, offering effective treatment options for a range of cancers, including metastatic diseases, with potential synergistic effects when combined with other anticancer therapies, enhancing therapeutic outcomes.
Implementation Method 1
crystalline polymorphic forms of 1,6-dibromo-1,6-dideoxy-dulcitol characterized by peaks at 19.59° (100,00) and 24.380° (79,52) and 31.260° (8,32) and 34.500° (25,56) and 34.810° (22,83) and 39.260° (23,63) at 2θ±0.1°
Implementation Method 2
the crystalline polymorph exhibits an endothermic point onset at about 184.4° C. and peak at approximately 191° C. as determined by differential scanning calorimetry
Data Source
AI summary
Described herein are polymorphic forms of 1,6-dibromo-1,6-dideoxy-dulcitol (dibromo dulcitol or DBD), which is a known antitumor agent. Also described are methods of making these new crystalline polymorphic forms as well as methods of using these polymorphic forms to treat cancer.